Randomized Etanercept North American Strategy to Study Antagonism of Cytokines - RENEWAL - RENAISSANCE

Description:

The goal of the Randomized Etanercept North American Strategy to Study Antagonism of Cytokine (RENAISSANCE) trial was to evaluate the efficacy of etanercept, a recombinant human tumor necrosis factor (TNF) receptor, compared with placebo among patients with chronic heart failure (CHF) and a left ventricular ejection fraction (LVEF) ≤30%.